<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02646800</url>
  </required_header>
  <id_info>
    <org_study_id>ACN-MA-MYC-registry-2013</org_study_id>
    <nct_id>NCT02646800</nct_id>
  </id_info>
  <brief_title>Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp</brief_title>
  <official_title>A Multi-center, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma China, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of intravenous micafungin
      for the treatment of adult patients in China infected by Candida spp or Aspergillus spp.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to administrative reasons
  </why_stopped>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by overall incidence and severity of adverse events for patients with candidiasis</measure>
    <time_frame>Up to a maximum of 10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by overall incidence and severity of adverse events for patients with aspergillosis</measure>
    <time_frame>Up to a maximum of 14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by adverse reactions for patients with candidiasis</measure>
    <time_frame>Up to a maximum of 10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by adverse reactions for patients with aspergillosis</measure>
    <time_frame>Up to a maximum of 14 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall success rate for patients with candidiasis</measure>
    <time_frame>End of treatment (up to up to 4 weeks, and up to 8 weeks for patients with chronic disseminated candidiasis, candida osteomyelitis, or candida endocarditis)</time_frame>
    <description>Overall success rate=number of overall success patients/number of patients for efficacy evaluation × 100% at end of treatment (overall success is defined as patients with complete or partial response)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall success rate for patients with aspergillosis</measure>
    <time_frame>End of treatment (up to 6 weeks, and up to 12 weeks for refractory patients)</time_frame>
    <description>Overall success rate=number of overall success patients/number of patients for efficacy evaluation × 100% at end of treatment (overall success is defined as patients with complete or partial response)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Improvement rate for patients with candidiasis</measure>
    <time_frame>End of treatment (up to up to 4 weeks, and up to 8 weeks for patients with chronic disseminated candidiasis, candida osteomyelitis, or candida endocarditis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Improvement rate for patients with aspergillosis</measure>
    <time_frame>End of treatment (up to 6 weeks, and up to 12 weeks for refractory patients)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fungal clearance rate for patients with candidiasis</measure>
    <time_frame>End of treatment (up to 4 weeks, and up to 8 weeks for patients with chronic disseminated candidiasis, candida osteomyelitis, or candida endocarditis)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fungal clearance rate for patients with aspergillosis</measure>
    <time_frame>End of treatment (up to 6 weeks, and up to 12 weeks for refractory patients</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatality rate for patients with candidiasis</measure>
    <time_frame>End of treatment (up to 4 weeks, and up to 8 weeks for patients with chronic disseminated candidiasis, candida osteomyelitis, or candida endocarditis)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatality rate for patients with aspergillosis</measure>
    <time_frame>End of treatment (up to 6 weeks, and up to 12 weeks for refractory patients</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by relationship of adverse events to Micafungin for patients with candidiasis</measure>
    <time_frame>Day 1 to the end of treatment (up to 4 weeks, and up to 8 weeks for patients with chronic disseminated candidiasis, candida osteomyelitis, or candida endocarditis)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by relationship of adverse events to Micafungin for patients with aspergillosis</measure>
    <time_frame>Day 1 to the end of treatment (up to 6 weeks, and up to 12 weeks for refractory patients)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by liver and kidney function for patients with candidiasis</measure>
    <time_frame>Day 1 to the end of treatment (up to 4 weeks, and up to 8 weeks for patients with chronic disseminated candidiasis, candida osteomyelitis, or candida endocarditis)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by liver and kidney function for patients with aspergillosis</measure>
    <time_frame>Day 1 to the end of treatment (up to 6 weeks, and up to 8 weeks, and up to 12 weeks for refractory patients)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Candidiasis</condition>
  <condition>Aspergillosis</condition>
  <arm_group>
    <arm_group_label>Micafungin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micafungin</intervention_name>
    <description>Injection</description>
    <arm_group_label>Micafungin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are diagnosed as proven/probable/possible fungal infection caused by
             Candida or Aspergillus based on the Chinese guidelines

          -  Females of childbearing potential must have a negative pregnancy test within 48 hrs
             prior to the study and reliable methods of contraception should be started 4 weeks
             prior to and during the whole study.

          -  Patients capable to understand the purposes and risks of the study, who are willing
             and able to participate in the study and from whom written and dated informed consent
             to participate in the study is obtained.

          -  Failure to fulfill inclusion criteria in another study, is not necessarily an
             exclusion criteria for this study, assuming other inclusion criteria 1-4 stated above
             are fulfilled.

        Exclusion Criteria:

          -  Patient has history of hypersensitivity, or any serious reaction to any component of
             this product or other echinocandins.

          -  Subject is unlikely to comply with the visits scheduled in the protocol in the opinion
             of investigator or has a history of non-compliance.

          -  Pregnant women, nursing mothers, lactating women, and women of child-bearing potential
             who are unwilling to use reliable contraception for the duration of the study and for
             6 weeks following completion of the study.

          -  AST/ALT &gt; 5 times the upper limit of normal (ULN)

          -  Total bilirubin&gt; 2.5 times ULN

          -  Patient has been previously enrolled in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harbin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hengyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Qingdao</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taiyuan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tianjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Urumchi</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=ACN-MA-MYC-registry-2013</url>
    <description>Link to results on Astellas Clinical Study Results Web site</description>
  </link>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2015</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>February 18, 2016</last_update_submitted>
  <last_update_submitted_qc>February 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Micafungin</keyword>
  <keyword>Candidiasis</keyword>
  <keyword>Aspergillosis</keyword>
  <keyword>Antifungal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Aspergillosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Micafungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

